Literature DB >> 2011043

Analysis of factors associated with bronchial hyperreactivity to methacholine in bronchiectasis.

M Ip1, W K Lam, S Y So, E Liong, C Y Chan, K M Tse.   

Abstract

Nonspecific bronchial hyperreactivity (BHR) has been reported to occur in patients with bronchiectasis. To evaluate this further, we studied 77 patients with stable bronchiectasis (noncystic fibrosis) with special reference to the prevalence of BHR to methacholine (MCh), and its relation to lung function, sputum characteristics, concommitant asthma, and atopy. The concentration of MCh required to produce a fall of 20% in forced expiratory volume in 1 s (FEV1), PC20, was determined by Wright's nebulization tidal breathing method. BHR defined by a PC20 greater than or equal to 8 mg/ml was found in 21 of 47 (45%) subjects who underwent bronchial challenge. Presence of BHR was positively associated with low baseline spirometric values, diagnosis of asthma, long duration of disease, and elevated total IgE on univariant analysis, and was significantly related to FEV1/forced vital capacity (FVC) ratio and asthma on multiple regression analysis. Ten of the 21 hyperreactive subjects did not have clinical asthma, whereas all 11 of 22 subjects with clinical asthma who underwent bronchial challenge were hyperreactive. Among those with BHR, there was a positive correlation between PC20 and baseline FEV1. When patients were further classified into asthmatic and nonasthmatic subjects, a positive correlation between PC20 and FEV1 was seen only in those without asthma. Frequency of infective episodes and inflammatory score of sputum assessed by average daily volume, purulence, and leukocyte count did not differ significantly in the groups with and without BHR. These results suggest that BHR in patients with bronchiectasis is associated with coexistent asthma and worse spriometric values, and not with the severity of bronchial sepsis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2011043     DOI: 10.1007/bf02714140

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  26 in total

1.  COMPARATIVE ACTION OF ACETYL-BETA-METHYL CHOLINE AND HISTAMINE ON THE RESPIRATORY TRACT IN NORMALS, PATIENTS WITH HAY FEVER, AND SUBJECTS WITH BRONCHIAL ASTHMA.

Authors:  J J Curry
Journal:  J Clin Invest       Date:  1947-05       Impact factor: 14.808

2.  Reduction in bronchial subdivision in bronchiectasis.

Authors:  L McA REID
Journal:  Thorax       Date:  1950-09       Impact factor: 9.139

3.  Bronchial reactivity to inhaled histamine: a method and clinical survey.

Authors:  D W Cockcroft; D N Killian; J J Mellon; F E Hargreave
Journal:  Clin Allergy       Date:  1977-05

4.  Airway conductance after inhalation of microaerosols of histamine chloride in healthy subjects and in patients with bronchiectasis before and after operation.

Authors:  A Holmgren; E Ripe
Journal:  Scand J Respir Dis       Date:  1973

5.  Nonspecificity of the bronchoconstricting effect of histamine and acetyl-beta-methylcholine in patients with obstructive airway disease.

Authors:  R C Klein; J E Salvaggio
Journal:  J Allergy       Date:  1966-03

6.  Differences in responsiveness to hyperventilation and methacholine in asthma and chronic bronchitis.

Authors:  E H Ramsdale; R S Roberts; M M Morris; F E Hargreave
Journal:  Thorax       Date:  1985-06       Impact factor: 9.139

7.  Pulmonary function studies in healthy Chinese adults in Singapore.

Authors:  J L da Costa
Journal:  Am Rev Respir Dis       Date:  1971-07

8.  Pulmonary function tests and airway responsiveness to methacholine in chronic bronchiectasis of the adult.

Authors:  J Bahous; A Cartier; L Pineau; C Bernard; H Ghezzo; R R Martin; J L Malo
Journal:  Bull Eur Physiopathol Respir       Date:  1984 Jul-Aug

Review 9.  The role of allergy and nonspecific airway hyperresponsiveness in the pathogenesis of chronic obstructive pulmonary disease.

Authors:  G T O'Connor; D Sparrow; S T Weiss
Journal:  Am Rev Respir Dis       Date:  1989-07

10.  Effect of long-term treatment with sodium cromoglycate on nonspecific bronchial hyperresponsiveness in asthma.

Authors:  S K Chhabra; S N Gaur
Journal:  Chest       Date:  1989-06       Impact factor: 9.410

View more
  7 in total

Review 1.  Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis?

Authors:  Paul King
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  Bronchial responsiveness and acute bronchodilator response in chronic obstructive pulmonary disease and diffuse panbronchiolitis.

Authors:  H Koyama; K Nishimura; T Mio; A Ikeda; N Sugiura; T Izumi
Journal:  Thorax       Date:  1994-06       Impact factor: 9.139

Review 3.  Performing a lung disability evaluation: how, when, and why?

Authors:  Akshay Sood
Journal:  J Occup Environ Med       Date:  2014-10       Impact factor: 2.162

4.  The effects of bronchiectasis on asthma exacerbation.

Authors:  Hye Ran Kang; Gyu-Sik Choi; Sun Jin Park; Yoon Kyung Song; Jeong Min Kim; Junghoon Ha; Yung Hee Lee; Byoung Hoon Lee; Sang-Hoon Kim; Jae Hyung Lee
Journal:  Tuberc Respir Dis (Seoul)       Date:  2014-11-28

5.  The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis.

Authors:  Hamdan Al-Jahdali; Abdullah Alshimemeri; Abdullah Mobeireek; Amr S Albanna; Nehad N Al Shirawi; Siraj Wali; Khaled Alkattan; Abdulrahman A Alrajhi; Khalid Mobaireek; Hassan S Alorainy; Mohamed S Al-Hajjaj; Anne B Chang; Stefano Aliberti
Journal:  Ann Thorac Med       Date:  2017 Jul-Sep       Impact factor: 2.219

6.  Inhaled Corticosteroid Therapy in Bronchiectasis is Associated with All-Cause Mortality: A Prospective Cohort Study.

Authors:  Kjell E J Håkansson; Katrine Fjaellegaard; Andrea Browatzki; Melda Dönmez Sin; Charlotte Suppli Ulrik
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-07-16

Review 7.  Inhaled corticosteroids for bronchiectasis.

Authors:  Nitin Kapur; Helen L Petsky; Scott Bell; John Kolbe; Anne B Chang
Journal:  Cochrane Database Syst Rev       Date:  2018-05-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.